CN111670032A - 预防或治疗阿尔茨海默氏病的方法 - Google Patents

预防或治疗阿尔茨海默氏病的方法 Download PDF

Info

Publication number
CN111670032A
CN111670032A CN201980011347.7A CN201980011347A CN111670032A CN 111670032 A CN111670032 A CN 111670032A CN 201980011347 A CN201980011347 A CN 201980011347A CN 111670032 A CN111670032 A CN 111670032A
Authority
CN
China
Prior art keywords
mice
subject
day
app
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980011347.7A
Other languages
English (en)
Chinese (zh)
Inventor
查尔斯·A·迪纳雷罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Olatec Therapeutics Inc
Original Assignee
Olatec Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Therapeutics Inc filed Critical Olatec Therapeutics Inc
Publication of CN111670032A publication Critical patent/CN111670032A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980011347.7A 2018-01-31 2019-01-31 预防或治疗阿尔茨海默氏病的方法 Pending CN111670032A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862624637P 2018-01-31 2018-01-31
US62/624,637 2018-01-31
PCT/US2019/016012 WO2019152627A1 (en) 2018-01-31 2019-01-31 Method for preventing or treating alzheimer's disease

Publications (1)

Publication Number Publication Date
CN111670032A true CN111670032A (zh) 2020-09-15

Family

ID=67478566

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980011347.7A Pending CN111670032A (zh) 2018-01-31 2019-01-31 预防或治疗阿尔茨海默氏病的方法

Country Status (7)

Country Link
US (1) US11517554B2 (https=)
EP (1) EP3746057B1 (https=)
JP (1) JP7290872B2 (https=)
CN (1) CN111670032A (https=)
CA (1) CA3087865A1 (https=)
MX (1) MX2020007941A (https=)
WO (1) WO2019152627A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7229565B2 (ja) * 2018-03-21 2023-02-28 オラテック セラピューティクス リミティド ライアビリティ カンパニー メラノーマを治療するための方法
EP4045009A4 (en) * 2019-10-14 2023-11-01 Olatec Therapeutics LLC METHOD FOR TREATING BREAST CANCER
CN117897151A (zh) * 2021-08-19 2024-04-16 欧拉泰克治疗公司 用于治疗帕金森氏病的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120157524A1 (en) * 2010-12-15 2012-06-21 St Laurent Joseph 3-methanesulfonylpropionitrile for treating inflammation and pain
WO2014066318A1 (en) * 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014194166A1 (en) * 2013-05-31 2014-12-04 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat alzheimer's disease
WO2015165961A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2016138425A1 (en) * 2015-02-26 2016-09-01 University Of Kentucky Research Foundation Compositions and methods for treating retinal degradation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120157524A1 (en) * 2010-12-15 2012-06-21 St Laurent Joseph 3-methanesulfonylpropionitrile for treating inflammation and pain
WO2014066318A1 (en) * 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARLO MARCHETTI ET AL: "OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation" *
DANIELS ET AL: "Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models" *
钟欣等: "NLRP3炎症小体与阿尔茨海默病研究进展" *

Also Published As

Publication number Publication date
JP2021512086A (ja) 2021-05-13
WO2019152627A1 (en) 2019-08-08
CA3087865A1 (en) 2019-08-08
EP3746057A1 (en) 2020-12-09
EP3746057B1 (en) 2024-03-20
EP3746057A4 (en) 2021-10-13
JP7290872B2 (ja) 2023-06-14
MX2020007941A (es) 2020-09-03
US20200352897A1 (en) 2020-11-12
US11517554B2 (en) 2022-12-06

Similar Documents

Publication Publication Date Title
CN108884053B (zh) 预防和/或治疗与衰老有关的认知障碍和神经炎症的方法
AU2005300727B2 (en) Use of Pirlindole for the treatment of diseases which are characterized by proliferation of T-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US20210283108A1 (en) Method for treating neurodegenerative diseases
US11517554B2 (en) Method for preventing or treating Alzheimer's disease
US20170151200A1 (en) Prophylactic or therapeutic agent for idiopathic inflammatory myopathies
WO2017060405A1 (en) Use of peptides to stimulate the immune system
US20160310481A1 (en) Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders
CN118593457B (zh) 芬戈莫德在制备治疗缺血性脑卒中口鼻吸入制剂中的应用
US5693614A (en) Drug for the treatment of senile dementia of the ischemic and hypoglycemic types
EP3151827B1 (en) Methods of treating chronic dry eye disease using c16:1n7 palmitoleate and derivatives thereof
US20210393549A1 (en) New use of R-enantiomer of adrenergic beta 2 receptor agonists for treatment of inflammatory bowel disease and its extra intestinal manifestations
US10548870B2 (en) Method for treating multiple sclerosis
CN115624543B (zh) 治疗偏头痛的药物、药物组合物、其制备方法和制药用途
Rubinow et al. CSF somatostatin in affective illness and normal volunteers
US11826340B1 (en) Method for treateing or preventing ischemic optic neuropathy
WO2022135462A1 (zh) Magl抑制剂的医药用途
US20240269104A1 (en) Method for treating parkinson's disease
EP3072521A1 (en) Use of recombined ganoderma lucidum immunoregulation protein (rlz-8) in preparing drugs for treating tissue fibrosis
Evanti et al. THE The efficacy of oral cyclosporine in a patient with drug reaction with eosinophilia and systemic symptoms probably due to cefadroxil
US20250367203A1 (en) Methods of treating epilepsy and reducing the incidence of seizures
JP7607939B2 (ja) 喘息を治療するための方法
US20220008402A1 (en) Increased e-cadherin expression or activity for the treatment of inflammatory diseases
CN105534882B (zh) 一种青霉胺鼻凝胶剂及其制备方法
CN117224519A (zh) L-犬尿氨酸作为一种免疫调节剂在器官移植中的应用
WO2017160079A2 (ko) 디케토피페라진을 유효성분으로 포함하는 전신염증질환의 치료용 약학적 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: USA New York

Applicant after: Oratec Treatment Co.

Address before: USA New York

Applicant before: OLATEC INDUSTRIES LLC

Country or region before: U.S.A.